NEW YORK, Aug. 26 - Synthetic RNA developer Dharmacon Research has secured $5.7 million in a Series A round of private-equity financing.
Boulder Ventures led the round, which included investments by Telegraph Hill Partners.
The company, based in Lafayette, Colo., said it will use the cash to bolster R&D and automation.